Voyager Therapeutics, Inc. Operating Lease, Expense
Voyager Therapeutics, Inc. (VYGR) reported Operating Lease, Expense of $1.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-06
- Voyager Therapeutics, Inc. operating lease, expense for the quarter ending 2026-06-30 was $1.80M, a 5.26% decline year-over-year.
- Voyager Therapeutics, Inc. operating lease, expense for the quarter ending 2026-03-31 was $1.90M, a 0.00% change year-over-year.
- Voyager Therapeutics, Inc. operating lease, expense for the quarter ending 2025-12-31 was $1.80M, a 10.00% decline year-over-year.
- Voyager Therapeutics, Inc. operating lease, expense for the quarter ending 2025-09-30 was $1.90M, a 0.00% change year-over-year.
- Voyager Therapeutics, Inc. operating lease, expense for fiscal 2025 was $7.50M, a 25.00% decline from fiscal 2024.
- Voyager Therapeutics, Inc. operating lease, expense for fiscal 2024 was $10.00M, a 177.78% increase from fiscal 2023.
- Voyager Therapeutics, Inc. operating lease, expense for fiscal 2023 was $3.60M, a 21.74% decline from fiscal 2022.
- Voyager Therapeutics, Inc. operating lease, expense for fiscal 2022 was $4.60M, a 32.35% decline from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.80M 10-Q · filed 2026-08-06 | $3.70M 10-Q · filed 2026-08-06 | $5.50M derived: sum of 3 quarters · filed 2026-08-06 | $7.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.90M 10-Q · filed 2026-05-07 | $3.70M derived: sum of 2 quarters · filed 2026-05-07 | $5.60M derived: sum of 3 quarters · filed 2026-05-07 | $7.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $3.70M derived: sum of 2 quarters · filed 2026-03-09 | $5.60M derived: sum of 3 quarters · filed 2026-08-06 | $7.50M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.90M 10-Q · filed 2025-11-10 | $3.80M derived: sum of 2 quarters · filed 2026-08-06 | $5.70M 10-Q · filed 2025-11-10 | $7.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.90M 10-Q · filed 2026-08-06 | $3.80M 10-Q · filed 2026-08-06 | $5.80M derived: sum of 3 quarters · filed 2026-08-06 | $7.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.90M 10-Q · filed 2026-05-07 | $3.90M derived: sum of 2 quarters · filed 2026-05-07 | $5.80M derived: sum of 3 quarters · filed 2026-05-07 | $10.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $3.90M derived: sum of 2 quarters · filed 2026-03-09 | $8.30M derived: sum of 3 quarters · filed 2026-03-09 | $10.00M 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.90M 10-Q · filed 2025-11-10 | $6.30M derived: sum of 2 quarters · filed 2025-11-10 | $8.00M 10-Q · filed 2025-11-10 | $8.90M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $4.40M 10-Q · filed 2025-08-06 | $6.10M 10-Q · filed 2025-08-06 | $7.00M derived: sum of 3 quarters · filed 2026-03-09 | $7.90M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $1.70M 10-Q · filed 2025-05-06 | $2.60M derived: sum of 2 quarters · filed 2026-03-09 | $3.50M derived: sum of 3 quarters · filed 2026-03-09 | $4.40M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.80M derived: sum of 2 quarters · filed 2026-03-09 | $2.70M derived: sum of 3 quarters · filed 2026-03-09 | $3.60M 10-K · filed 2026-03-09 |
| 2023-09-30 | $900.00K 10-Q · filed 2024-11-12 | $1.80M derived: sum of 2 quarters · filed 2024-11-12 | $2.70M 10-Q · filed 2024-11-12 | $3.50M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $900.00K 10-Q · filed 2024-08-06 | $1.80M 10-Q · filed 2024-08-06 | $2.60M derived: sum of 3 quarters · filed 2025-03-11 | $3.60M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $900.00K 10-Q · filed 2024-05-13 | $1.70M derived: sum of 2 quarters · filed 2025-03-11 | $2.70M derived: sum of 3 quarters · filed 2025-03-11 | $4.10M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.80M derived: sum of 2 quarters · filed 2025-03-11 | $3.20M derived: sum of 3 quarters · filed 2025-03-11 | $4.60M 10-K · filed 2025-03-11 |
| 2022-09-30 | $1.00M 10-Q · filed 2023-11-06 | $2.40M derived: sum of 2 quarters · filed 2023-11-06 | $3.80M 10-Q · filed 2023-11-06 | $5.20M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $1.40M 10-Q · filed 2023-08-03 | $2.80M 10-Q · filed 2023-08-03 | $4.20M derived: sum of 3 quarters · filed 2024-02-28 | $5.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.40M 10-Q · filed 2023-05-09 | $2.80M derived: sum of 2 quarters · filed 2024-02-28 | $4.50M derived: sum of 3 quarters · filed 2024-02-28 | $6.40M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $3.10M derived: sum of 2 quarters · filed 2024-02-28 | $5.00M derived: sum of 3 quarters · filed 2024-02-28 | $6.80M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.70M 10-Q · filed 2022-11-08 | $3.60M derived: sum of 2 quarters · filed 2022-11-08 | $5.40M 10-Q · filed 2022-11-08 | $6.60M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $1.90M 10-Q · filed 2022-08-04 | $3.70M 10-Q · filed 2022-08-04 | $4.90M derived: sum of 3 quarters · filed 2023-03-07 | $6.50M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $1.80M 10-Q · filed 2022-05-04 | $3.00M derived: sum of 2 quarters · filed 2023-03-07 | $4.60M derived: sum of 3 quarters · filed 2023-03-07 | $6.30M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $2.80M derived: sum of 2 quarters · filed 2023-03-07 | $4.50M derived: sum of 3 quarters · filed 2023-03-07 | $6.20M 10-K · filed 2023-03-07 |
| 2020-09-30 | $1.60M 10-Q · filed 2021-11-02 | $3.30M derived: sum of 2 quarters · filed 2021-11-02 | $5.00M 10-Q · filed 2021-11-02 | $6.70M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | $1.70M 10-Q · filed 2021-08-09 | $3.40M 10-Q · filed 2021-08-09 | $5.10M derived: sum of 3 quarters · filed 2022-03-08 | $6.20M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $1.80M 10-Q · filed 2021-05-10 | $3.40M derived: sum of 2 quarters · filed 2022-03-08 | $4.50M derived: sum of 3 quarters · filed 2022-03-08 | $6.10M derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $2.70M derived: sum of 2 quarters · filed 2022-03-08 | $4.30M derived: sum of 3 quarters · filed 2022-03-08 | $5.70M 10-K · filed 2022-03-08 |
| 2019-09-30 | $1.10M 10-Q · filed 2020-11-09 | $2.70M derived: sum of 2 quarters · filed 2020-11-09 | $4.10M 10-Q · filed 2020-11-09 | $5.30M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.60M 10-Q · filed 2019-08-09 | $3.00M 10-Q · filed 2019-08-09 | $4.20M derived: sum of 3 quarters · filed 2021-02-25 | $5.20M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $1.40M 10-Q · filed 2020-05-06 | $2.60M derived: sum of 2 quarters · filed 2021-02-25 | $3.60M derived: sum of 3 quarters · filed 2021-02-25 | $4.60M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.20M derived: sum of 2 quarters · filed 2021-02-25 | $3.20M derived: sum of 3 quarters · filed 2021-02-25 | $4.00M 10-K · filed 2021-02-25 |
| 2018-09-30 | $1.00M 10-Q · filed 2019-11-06 | $2.00M derived: sum of 2 quarters · filed 2019-11-06 | $2.80M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $1.00M 10-Q · filed 2019-08-09 | $1.80M 10-Q · filed 2019-08-09 | ||
| 2017-12-31 | $2.90M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |